Considerations in the Pharmacologic Treatment and Prevention of Neonatal Sepsis

[1]  S. Abrams,et al.  Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. , 2015, The Cochrane database of systematic reviews.

[2]  L. Cuzzolin.  Drug metabolizing enzymes in the perinatal and neonatal period: differences in the expression and activity. , 2013, Current drug metabolism.

[3]  T. Fleisher.  Treatment of Neonatal Sepsis With Intravenous Immune Globulin , 2012, Pediatrics.

[4]  J. Dorling,et al.  Lactoferrin immunoprophylaxis for very preterm infants , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[5]  S. Yaffe,et al.  Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice , 2012 .

[6]  D. Benjamin,et al.  Therapeutic Monitoring of Voriconazole in Children Less Than Three Years of Age: A Case Report and Summary of Voriconazole Concentrations for Ten Children , 2012, The Pediatric infectious disease journal.

[7]  D. Peebles,et al.  Immune Status in Very Preterm Neonates , 2012, Pediatrics.

[8]  S. Magill,et al.  Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit. , 2011, The Journal of hospital infection.

[9]  M. Sharland,et al.  Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units. , 2011, The Journal of antimicrobial chemotherapy.

[10]  P. Brocklehurst,et al.  Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. , 2011, The Cochrane database of systematic reviews.

[11]  P. Smith,et al.  Fluconazole Loading Dose Pharmacokinetics and Safety in Infants , 2011, The Pediatric infectious disease journal.

[12]  B. Poindexter,et al.  Early Onset Neonatal Sepsis: The Burden of Group B Streptococcal and E. coli Disease Continues , 2011, Pediatrics.

[13]  M. Mostert,et al.  Antifungal prophylaxis in neonates. , 2011, Early human development.

[14]  Stephanie Schrag,et al.  Prevention of Perinatal Group B Streptococcal Disease Revised Guidelines from CDC , 2002 .

[15]  B. Poindexter,et al.  Neonatal Candidiasis: Epidemiology, Risk Factors, and Clinical Judgment , 2010, Pediatrics.

[16]  N. Kennea,et al.  Neonatal infections in England: the NeonIN surveillance network , 2010, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[17]  D. Kaufman,et al.  Strategies to prevent invasive candidal infection in extremely preterm infants. , 2010, Clinics in perinatology.

[18]  E. Roilides,et al.  Use of linezolid in pediatrics: a critical review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[19]  C. Subudhi,et al.  Aspergillus fumigatus: A Potentially Lethal Ubiquitous Fungus in Extremely Low Birthweight Neonates , 2010, Pediatric dermatology.

[20]  P. Smith,et al.  Population Pharmacokinetics of Micafungin in Neonates and Young Infants , 2010, Antimicrobial Agents and Chemotherapy.

[21]  C Michael Cotten,et al.  Early and Late Onset Sepsis in Late Preterm Infants , 2009, The Pediatric infectious disease journal.

[22]  J. Anker,et al.  Therapeutic Drug Monitoring of Aminoglycosides in Neonates , 2009 .

[23]  G. Anderson,et al.  Optimizing Pediatric Dosing: A Developmental Pharmacologic Approach , 2009, Pharmacotherapy.

[24]  D. Kaufman,et al.  Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates , 2009, The Pediatric infectious disease journal.

[25]  E. Shuman,et al.  Infection Prevention and Control: Theory and Practice for Healthcare Professionals. , 2009 .

[26]  M. Coulthard,et al.  Human renal function maturation: a quantitative description using weight and postmenstrual age , 2009, Pediatric Nephrology.

[27]  W. Schaffner,et al.  Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease: A Multistate, Population-Based Analysis , 2008, The Pediatric infectious disease journal.

[28]  D. Kaufman,et al.  Population Pharmacokinetics of Fluconazole in Young Infants , 2008, Antimicrobial Agents and Chemotherapy.

[29]  C. Doré,et al.  A case definition for national and international neonatal bloodstream infection surveillance , 2008, Archives of Disease in Childhood Fetal and Neonatal Edition.

[30]  R. Schelonka,et al.  Genital Tract Methicillin-Resistant Staphylococcus aureus: Risk of Vertical Transmission in Pregnant Women , 2008, Obstetrics and gynecology.

[31]  A. Shad,et al.  Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing , 2007, Antimicrobial Agents and Chemotherapy.

[32]  F. de Zegher,et al.  Renal Drug Clearance in Preterm Neonates: Relation to Prenatal Growth , 2007, Therapeutic drug monitoring.

[33]  G. Bein,et al.  Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections , 2006, Transfusion.

[34]  B. Stoll,et al.  The Association of Third-Generation Cephalosporin Use and Invasive Candidiasis in Extremely Low Birth-Weight Infants , 2006, Pediatrics.

[35]  J. N. van den Anker,et al.  Pharmacological research in pediatrics: From neonates to adolescents. , 2006, Advanced drug delivery reviews.

[36]  R. C. Silveira,et al.  Empiric guidelines for treatment of Candida infection in high-risk neonates , 2006, European Journal of Pediatrics.

[37]  William Oh,et al.  Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months , 2006, Pediatrics.

[38]  G. Hempel,et al.  Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates , 2005, Antimicrobial Agents and Chemotherapy.

[39]  A. Shad,et al.  Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents , 2005, Antimicrobial Agents and Chemotherapy.

[40]  P. Valenti,et al.  Lactoferrin , 2005, Cellular and Molecular Life Sciences.

[41]  R. Baltimore,et al.  Seventy-Five Years of Neonatal Sepsis at Yale: 1928–2003 , 2005, Pediatrics.

[42]  M. Richardson,et al.  Changing patterns and trends in systemic fungal infections. , 2005, The Journal of antimicrobial chemotherapy.

[43]  J. N. van den Anker,et al.  New dosing strategies for antibacterial agents in the neonate. , 2005, Seminars in fetal & neonatal medicine.

[44]  B. Vohr,et al.  Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. , 2004, JAMA.

[45]  Judith R. Campbell,et al.  Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  Y. Lau,et al.  Hand Hygiene Practices in a Neonatal Intensive Care Unit: A Multimodal Intervention and Impact on Nosocomial Infection , 2004, Pediatrics.

[47]  Allan R Tunkel,et al.  Practice guidelines for the management of bacterial meningitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  D. Kaufman,et al.  Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants , 2004, Clinical Microbiology Reviews.

[49]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  W. Tarnow-Mordi,et al.  Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants? , 2004, Archives of disease in childhood. Fetal and neonatal edition.

[51]  E. E. El Desoky,et al.  Aminoglycoside and vancomycin serum concentration monitoring and mortality due to neonatal sepsis in Saudi Arabia , 2003, Journal of clinical pharmacy and therapeutics.

[52]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[53]  P. Azimi,et al.  Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates , 2003, The Pediatric infectious disease journal.

[54]  T. Walsh,et al.  Empirical therapy for neonatal candidemia in very low birth weight infants. , 2003, Pediatrics.

[55]  R. Polin,et al.  The "ins and outs" of neonatal sepsis. , 2003, The Journal of pediatrics.

[56]  R. Booy,et al.  Diagnosis and treatment of bacterial meningitis , 2003, Archives of disease in childhood.

[57]  X. Sáez-Llorens,et al.  Bacterial meningitis in children. , 2005, Pediatric clinics of North America.

[58]  C. Baker,et al.  Group B streptococcal conjugate vaccines , 2003, Archives of disease in childhood.

[59]  R. Guillet,et al.  A Gentamicin Pharmacokinetic Population Model and Once‐Daily Dosing Algorithm for Neonates , 2003, Pharmacotherapy.

[60]  M. Korotkova,et al.  The role of breastfeeding in prevention of neonatal infection. , 2002, Seminars in neonatology : SN.

[61]  W. Poole,et al.  Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. , 2002, Pediatrics.

[62]  P. Lees,et al.  Rational dosing of antimicrobial drugs: animals versus humans. , 2002, International journal of antimicrobial agents.

[63]  C. W. Yoxall,et al.  Time to positivity of neonatal blood cultures , 2001, Archives of disease in childhood. Fetal and neonatal edition.

[64]  P. Duff,et al.  Infection, antibiotics, and preterm delivery. , 2001, Seminars in perinatology.

[65]  B. Mogilner,et al.  Liposomal Amphotericin B (AmBisome) in the Treatment of Neonatal Candidiasis in Very Low Birth Weight Infants , 2000, Infection.

[66]  W. Hayton.  Maturation and growth of renal function: Dosing renally cleared drugs in children , 2000, AAPS PharmSci.

[67]  A. Schuchat,et al.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.

[68]  G. Kearns,et al.  Cytochrome P450 3A , 1999, Clinical pharmacokinetics.

[69]  C. Speer,et al.  Inflammatory mechanisms in neonatal chronic lung disease , 1999, European Journal of Pediatrics.

[70]  V. Quagliarello,et al.  Treatment of bacterial meningitis , 1999, Comprehensive therapy.

[71]  R. Schoemaker,et al.  Tobramycin population pharmacokinetics in neonates * , 1997 .

[72]  V. Jn.  Antifungal agents in neonatal systemic candidiasis. , 1997 .

[73]  T. Cresteil,et al.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.

[74]  K. Rodvold,et al.  Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children , 1997, Clinical pharmacokinetics.

[75]  Michael H. Goodstein,et al.  Frequency of low level bacteremia in infants from birth to two months of age. , 1997, The Pediatric infectious disease journal.

[76]  J. Sonntag,et al.  Serum creatinine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1500 g , 1996, European Journal of Pediatrics.

[77]  K. Michaelsen,et al.  Decreased thymus size in formula‐fed infants compared with breastfed infants , 1996, Acta paediatrica.

[78]  Robert L. Schelonka,et al.  Volume of blood required to detect common neonatal pathogens. , 1996 .

[79]  R. Christensen,et al.  Neutropenia in the neonate. , 1995, Clinics in perinatology.

[80]  G. Kearns,et al.  Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children , 1995, Antimicrobial agents and chemotherapy.

[81]  William A. Catterall,et al.  Ins and outs , 1994, Nature.

[82]  D. Gibbs,et al.  Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[83]  K. Waites,et al.  Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection. , 1994, The Pediatric infectious disease journal.

[84]  A. Goldman.  The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. , 1993, The Pediatric infectious disease journal.

[85]  H. Hill.  Intravenous immunoglobulin use in the neonate: role in prophylaxis and therapy of infection , 1993, The Pediatric infectious disease journal.

[86]  D. Tudehope,et al.  Hematologic scoring system in early diagnosis of sepsis in neutropenic newborns. , 1993, The Pediatric infectious disease journal.

[87]  R. Ashraf,et al.  Breast feeding and protection against neonatal sepsis in a high risk population. , 1991, Archives of disease in childhood.

[88]  H. Hill,et al.  Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis. , 1991, The Journal of pediatrics.

[89]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[90]  M. Nahata,et al.  Clinical Pharmacokinetics of Antibacterial Drugs in Neonates , 1990, Clinical pharmacokinetics.

[91]  W. Heird,et al.  Antiviral and antibacterial lipids in human milk and infant formula feeds. , 1990, Archives of disease in childhood.

[92]  R. Kliegman,et al.  Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. , 1990, The Journal of pediatrics.

[93]  M. Sande,et al.  Pathophysiology of bacterial meningitis: summary of the workshop. , 1989, The Pediatric infectious disease journal.

[94]  P. Scott.  Plasma Lactoferrin Levels in Newborn Preterm Infants: Effect of Infection , 1989, Annals of clinical biochemistry.

[95]  M. Mustafa,et al.  Antimicrobial agents in pediatrics. , 1989, Infectious disease clinics of North America.

[96]  Henry Nider,et al.  Report of the Committee on Infectious Diseases , 1989 .

[97]  J. Hirsch,et al.  Brain abscesses in neonates. A study of 30 cases. , 1988, Journal of neurosurgery.

[98]  J. Baley.  Neonatal sepsis: the potential for immunotherapy. , 1988, Clinics in perinatology.

[99]  P. A. Todd,et al.  Imipenem/Cilastatin , 1987, Drugs.

[100]  D. Nierenberg.  Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings. , 1987, The Journal of pharmacology and experimental therapeutics.

[101]  B. Ljungberg,et al.  Pharmacokinetics of antimicrobial agents in the elderly. , 1987, Reviews of infectious diseases.

[102]  M. Ballow,et al.  Development of The Immune System in Very Low Birth Weight (Less than 1500 g) Premature Infants: Concentrations of Plasma Immunoglobulins and Patterns of Infections , 1986, Pediatric Research.

[103]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[104]  J. Klein,et al.  Infectious Diseases of the Fetus and Newborn Infant , 1983 .

[105]  D. Goldmann,et al.  Nosocomial infections in a neonatal intensive care unit. , 1981, The Journal of infectious diseases.

[106]  D. Graham,et al.  Citrobacter diversus brain abscess and meningitis in neonates. , 1981, JAMA.

[107]  M. Pichichero,et al.  Detection of neonatal bacteremia. , 1979, The Journal of pediatrics.

[108]  E. Cooperman.  Report of the Committee on Infectious Diseases , 1978, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[109]  M. Gupta,et al.  Gastric retention in neonates. , 1978, Pediatrics.

[110]  G. Siber,et al.  Pharmacokinetics of gentamicin in children and adults. , 1975, The Journal of infectious diseases.

[111]  H. Yoshioka,et al.  Pharmacokinetics of ampicillin in the newborn infant. , 1974, The Journal of infectious diseases.

[112]  M. Ehrnebo,et al.  Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults , 1971, European Journal of Clinical Pharmacology.

[113]  J. Winberg,et al.  Does breast milk protect against septicaemia in the newborn? , 1971, Lancet.

[114]  B. Friis‐Hansen.  Body water compartments in children: changes during growth and related changes in body composition. , 1961, Pediatrics.

[115]  N. Huang,et al.  Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. , 1953, The Journal of pediatrics.

[116]  C. Baker,et al.  92 – Bacterial Infections in the Neonate , 2012 .

[117]  Patricia J. Johnson.  Neonatal Pharmacology—Pharmacokinetics , 2011, Neonatal Network.

[118]  J. Stockman.  Evaluation of Universal Antenatal Screening for Group B Streptococcus , 2011 .

[119]  V. Nizet,et al.  CHAPTER 6 – Bacterial Sepsis and Meningitis , 2011 .

[120]  D. Adamkin.  Bovine Lactoferrin Supplementation for Prevention of Late-Onset Sepsis in Very Low-Birth-Weight Neonates: A Randomized Trial , 2010 .

[121]  A. Ohlsson,et al.  Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. , 2010, The Cochrane database of systematic reviews.

[122]  S. Schrag,et al.  Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[123]  J. N. van den Anker.  Developmental pharmacology. , 2010, Developmental disabilities research reviews.

[124]  D. Tibboel,et al.  Pain management in intellectually disabled children: Assessment, treatment, and translational research. , 2010, Developmental disabilities research reviews.

[125]  S. Schrag,et al.  Morbidity and Mortality Weekly Report (MMWR) Prevention of Perinatal Group B Streptococcal Disease Revised Guidelines from CDC, 2010 Recommendations and Reports , 2010 .

[126]  T. Walsh,et al.  Invasive zygomycosis in neonates and children. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[127]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[128]  T. Ochoa,et al.  Effect of lactoferrin on enteric pathogens. , 2009, Biochimie.

[129]  D. Legrand,et al.  Lactoferrin structure and functions. , 2008, Advances in experimental medicine and biology.

[130]  Debbie Weston,et al.  Infection Prevention and Control , 2008 .

[131]  R. H. Albert,et al.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. , 2010 .

[132]  P. Toltzis.  Empiric Use of Ampicillin and Cefotaxime, Compared With Ampicillin and Gentamicin, for Neonates at Risk for Sepsis Is Associated With an Increased Risk of Neonatal Death , 2007 .

[133]  Alan Forrest,et al.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[134]  C. Prober.  Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months , 2007 .

[135]  J. Klein,et al.  Bacterial Sepsis and Meningitis , 2006 .

[136]  A. Ohlsson,et al.  Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. , 2004, The Cochrane database of systematic reviews.

[137]  A. Windorfer,et al.  The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding , 2004, European Journal of Clinical Pharmacology.

[138]  L. Saravolatz,et al.  Broad-range bacterial polymerase chain reaction for early detection of bacterial meningitis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[139]  L. Dans,et al.  Intravenous immunoglobulin for treating sepsis and septic shock. , 2000, The Cochrane database of systematic reviews.

[140]  I. Adlerberth,et al.  Pathological Consequences of Commensalism , 2000 .

[141]  J. N. van den Anker,et al.  Vancomycin population pharmacokinetics in neonates. , 2000, Clinical pharmacology and therapeutics.

[142]  M. Blaser,et al.  Persistent bacterial infections , 2000 .

[143]  Robert H. Yolken,et al.  Probiotics, other nutritional factors, and intestinal microflora , 1999 .

[144]  G. Koren.  Therapeutic drug monitoring principles in the neonate , 1997 .

[145]  G. Koren.  Therapeutic drug monitoring principles in the neonate. National Academy of CLinical Biochemistry. , 1997, Clinical chemistry.

[146]  J. Hirsch,et al.  A study of 30 cases , 1988 .